• Halozyme Therapeutics EPS for the quarter ending December 31, 2024 was $1.06, a 65.63% increase year-over-year.
• Halozyme Therapeutics 2024 annual EPS was $3.43, a 63.33% increase from 2023.
• Halozyme Therapeutics 2023 annual EPS was $2.1, a 45.83% increase from 2022.
• Halozyme Therapeutics 2022 annual EPS was $1.44, a 47.45% decline from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.